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Abstract 
 
 Raman spectroscopy is a non-destructive, non-invasive, rapid and economical 
technique which has the potential to be an excellent method for the diagnosis of cancer and 
understanding disease progression through retrospective studies of archived tissue samples. 
Historically, biobanks are generally comprised of formalin fixed paraffin preserved tissue and 
as a result these specimens are often used in spectroscopic research. Tissue in this state has to 
be dewaxed prior to Raman analysis to reduce paraffin contributions in the spectra. However, 
although the procedures are derived from histopathological clinical practice, the efficacy of 
the dewaxing procedures that are currently employed is questionable. Ineffective removal of 
paraffin results in corruption of the spectra and previous experiments have shown that the 
efficacy can depend on the dewaxing medium and processing time. The aim of this study was 
to investigate the influence of commonly used spectroscopic substrates (CaF2, Spectrosil 
quartz and low-E slides) and the influence of different histological tissue types (normal, 
cancerous and metastatic) on tissue preparation and to assess their use for spectral 
histopathology. Results show that CaF2 followed by Spectrosil contribute the least to the 
spectral background. However, both substrates retain paraffin after dewaxing. Low-E 
substrates, which exhibit the most intense spectral background, do not retain wax and 
resulting spectra are not affected by paraffin peaks. We also show a disparity in paraffin 
retention depending upon the histological identity of the tissue with abnormal tissue retaining 
more paraffin than normal. 
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Introduction 
 
The primary requirement for successful treatment of any disease is early detection. 
Cancer incidence rates have continued to rise 
1
, although survival rates for cancer are 
increased with early diagnosis. Current methods used in cancer diagnosis focus on changes in 
architecture of tissue, cells or internal constituents and the identification of protein 
expression. Research performed into identification of protein expression in blood has 
produced single biomarkers for specific cancers that have become misleading. There have 
been many studies of different pathologies but the issues are well demonstrated by the 
example of prostate cancer. The Prostate Specific Antigen (PSA) test is used to indicate 
prostate cancer (CaP). However, approximately 40 % of organ confined CaP show no 
elevation of PSA 
2
 and many other benign conditions can show increased PSA serum, thus 
producing false positives in screening. Hoffman et al. suggest that CaP screening would 
benefit from improved biomarkers, which more readily identify clinically important cancers 
3
. As cancer is a heterogeneous disease, a set of markers or a whole sample profile will 
provide significantly more diagnostic information than any one marker 
4
. After initial 
indication of cancer, diagnosis is confirmed by biopsy and assessment of tissue architecture. 
The biopsy is assessed based upon a subjective measurement. For CaP this is called the 
Gleason grading system and in a study of 390 patients identical grades were assigned to only 
29.2% of the tumours by different histopathologists 
5
. Pathological discrepancies are reported 
to occur in up to 43% of specimens assessed via histopathology 
6
. The accurate and rapid 
diagnosis of disease allows early intervention of appropriate treatment, thus increasing life 
expectancy and reducing healthcare costs 
7
. Therefore, there is a requirement for non-
subjective techniques that can rapidly and accurately identify disease. 
 Spectroscopic techniques, such as Raman and Infrared (IR), are excellent methods for 
the analysis of a wide range of materials. They are non-destructive, rapid, cost-effective and 
simple to operate. The inelastic (Raman) scattered light from molecules under irradiation is 
wavelength-shifted with respect to the incident light by molecular vibrations. The Raman 
spectrum is complementary to that of IR which represents the absorption of incident light at 
the resonant frequency of the bond or group, exciting vibrational modes. Different 
biomolecules exhibit responses to different wavelengths of light; the resultant spectrum can 
be thought of as a ‘fingerprint’ of the sample. Spectroscopic analysis allows the objective 
classification of biological material on a molecular level
8
. Previous studies have 
demonstrated the use of spectroscopy (imaging and point spectra) to analyse gastrointestinal 
(GI) tract 
9, 10
, lung 
11, 12
, cervix 
13, 14
, brain 
15, 16
,breast 
17, 18
, prostate 
19-21
 and lymph node 
cancers 
22, 23
. Initial work has focused on differentiating between normal tissue and advanced 
cancers. Technological development is enabling diagnosis at progressively earlier stages and 
potential to do so in vivo 
24
. The aim of these studies is to develop spectral histopathology 
based upon objective chemical information. 
 
In order to develop spectral histopathology, a database of tissue spectra is required to 
enable spectral disease identification. The ideal situation would be to build this database 
using fresh or frozen tissue sections. However, historically, biobanks have been built using 
Formalin Fixed Paraffin Preserved Tissue (FFPP) sections, which are fixed using formalin 
and impregnated with paraffin wax to preserve the tissue for future analysis and provide 
support to aid microtomy for sectioning the tissue block to enable microscopic examination. 
Prior to histological and/or spectral analysis, the tissue sections generally undergo a 
dewaxing process, to allow histological staining of the tissue for pathological examination 
and to reduce paraffin contributions in vibrational spectra, consequently, returning the tissue 
to as much of an in vivo state as possible 
25
. 
 
Ó Faoláin et al. investigated the efficacy of dewaxing procedures on formalin fixed, 
paraffin preserved (FFPP) cervical tissue on glass slides 
25
. They reported that dewaxing 
procedures employing, the commonly used xylene and HistoClear solvents do not completely 
remove all of the paraffin wax. Although, they found hexane to be a much more efficient 
dewaxing agent, it requires 18 hours of tissue submersion and is not clinically used for 
dewaxing procedures 
25
. An important advantage in using spectroscopy for diagnosis is the 
short diagnostic window; therefore, a dewaxing solvent that requires a long processing time 
period is not an attractive option for this field of study. Ó Faoláin et al. indicate that Raman 
spectroscopy is much more sensitive to assess the incomplete removal of wax than FTIR. 
This was concluded following analysis of Raman and FTIR spectra obtained from identically 
deparaffinised tissue sections in which spectral peaks characteristic of paraffin wax were 
more clearly resolved in Raman spectra (strong sharp bands), compared with FTIR spectra 
26
. 
 
The contribution of paraffin peaks in vibrational spectra is apparent in both infrared 
and Raman spectroscopy. However, these peaks appear more prominently in the spectra of 
the latter technique; thus, Raman spectroscopy was used in this study to analyse the efficacies 
of current dewaxing techniques.  
 
Substrates are needed in spectral histopathology to support the samples during 
analysis. Samples are often relatively thin allowing incident light the opportunity of 
interacting with the substrate below. This interaction has an effect on the spectral 
background; thus, the correct choice of substrate for spectroscopic analysis is essential for 
reducing this background and optimising the quality of the spectral data 
27
. Commercial glass 
microscope slides exhibit a very large fluorescent background under excitation in the near 
infrared, and are thus not suitable. Therefore, common spectroscopy substrates currently used 
include quartz, CaF2 and low-E microscope slides, the latter being relatively low cost.
28 
 
Recently, the choice of substrate has been a hot topic within the spectral 
histopathology field, as spectral artefacts have been identified in FTIR transflection analysis 
using highly reflective low-E slides
29,30
. However, when analysing tissue, a 2
nd
 derivative 
spectrum minimises these contributions allowing for spectral histopathological diagnosis31.  
Both quartz and CaF2 are transparent over a large range of the mid-IR and are therefore 
suitable for transmission measurements, although CaF2 has been shown to be better for 
Raman measurements, and so is an obvious choice for use of both complementary 
techniques. The choice of substrate is also important if spectral diagnoses are going to be 
effective in the clinical setting, substrates that can easily fit into current methodologies (due 
to size, solubility etc.) are advantageous and also cost needs to be minimised to ensure 
efficient health services. 
 
Vibrational spectroscopy has the potential to revolutionise the clinical environment, 
allowing for increased efficiency within the diagnostic regime with corresponding decreases 
in mortality, morbidity and economic impact upon the health services 
32
.  In order to achieve 
this potential, research needs to be performed to understand the impact of sample preparation 
upon the vibrational spectrum. We present, for the first time, a study of the effect and 
efficiency of the dewaxing process, using a clinical standard HistoClear procedure, by 
substrate and tissue type utilising Raman spectroscopy in order to develop the basis of 
standard approaches for spectral histopathology. 
 
Experimental 
 
Study participants 
 
Tissue sections cut, by microtomy, at both 4 µm onto glass microscope slides and 10 
µm onto spectroscopic substrates: low-E MirrIR slides (Kevley Technologies, Chesterland, 
OH, 44026, USA), Spectrosil quartz (Starna Scientific) and calcium fluoride (CaF2) 
(Crystran), were obtained from formalin fixed paraffin preserved (FFPP) tissue blocks from 
the Brain Tumour North West (BTNW) bio-bank under ethical approval (BTNW/WRTB 
13_01). The substrates had not been used for prior investigations and were fresh for this 
study. The measurements were taken from multiple slides and multiple places on each slide so batch 
to batch variability should not affect the trends in the data shown. The tissue sections used from 
each sample were cut consecutively with one section used for Raman analysis and one for 
haematoxylin and eosin staining. Patient data consisted of histological information, patient 
gender and date of birth, origin of metastasis/histological subtype. A total of 48 tissue 
specimens were obtained from 41 different patients. Tissue consisted of normal brain samples 
(n=7), glioblastoma multiforme (GBM) brain samples WHO (World Health Organisation) 
grade IV (n=5) and metastatic brain samples (n=29). Table 1 displays further information 
about the tissue specimens.  
 
 
 Dewaxing and Haematoxylin and Eosin staining of tissue 
 
Tissue sections on the microscope slides needed to undergo staining with 
haematoxylin and eosin (H&E) for parallel histological examination. The sections were de-
waxed before staining, carried out by: 2 x 5 minute baths of HistoClear followed by 2 x 5 
minute baths of ethanol. The tissue sections were washed in distilled water for 5 minutes after 
de-waxing, prior to H&E staining. Sections were bathed in haematoxylin for 5 minutes and 
then washed in warm tap water to allow the nuclei to turn blue. The sections were then 
covered in eosin for 4 minutes and rinsed with distilled water. Finally, the tissue sections 
were dehydrated in 2 x 5 minute baths of ethanol and cleared in 2 x 5 minute baths of 
histoclear, and then protected and preserved through the application of HistoMount and a 
coverslip. The sections were then microscopically examined in order to identify the 
metastatic sites present in the tissue.   
 
Figure 1 shows the microscopic images of the H & E stained tissue samples at x 100 
magnification. It can be observed that normal brain, metastatic and GBM brain tissue 
architecturally differ from one another and between the metastatic types. 
 
Tissue section preparation for Raman spectroscopic analysis 
 
 The tissue sections on Raman substrates needed to be de-waxed prior to Raman 
analysis in order to reduce the paraffin peak contributions in the spectra. The de-waxing 
procedure consisted of 3 x 5 minute baths of HistoClear followed by 3 x 5 minute baths of 
ethanol. The sections were left to air dry for 30 minutes, placed in a Petri dish and stored in a 
desiccator until spectroscopic analysis. 
 
  
Raman spectroscopy instrumentation and analysis 
Spectroscopic measurements were carried out using a Horiba Jobin-Yvon LabRAM HR800 
spectrometer. An air cooled CLDS point mode diode 785 nm laser with a single edge filter  
(cut off to 100 cm
-1
)
 
and an output power of 300 mW was used to acquire spectra; which was 
used with a grating of 300 gr/mm and blazed at 1000 nm. Point spectra were acquired using a 
x 100 (Olympus MPlanN, NA = 0.9, spotsize ~1µm) objective and immersion point spectra 
were taken using a x 60 (Olympus LUMPlanFLN, NA = 1.0, spotsize ~ 1.5µm). Immersion 
spectroscopy was used for measurement of the tissue samples for spectral histopathology. 
Immersion Raman utilises an immersion lens which is in direct contact with a liquid that the 
sample under analysis is submerged in, such as deionised water used in this study. Bonnier et 
al. describe the use of immersion Raman spectroscopy and demonstrate its successful use for 
improving spectral quality
34,35
. 
 
The confocal hole was set at 100 µm for 785 nm spectral collections. The detector used was 
an Andor charged coupled device (CCD). A video camera within the Raman system was used 
to take images of the specimens. The instrumentation was calibrated before operation to 
silicon at the spectral line of 520.8 cm
-1
. Spectra were acquired using the 785 nm laser at 
100% exposure for 30 s and accumulated twice. From each tissue section 20 spectra were 
acquired from different regions, depending upon the size of the tissue slice. 
 
For all tissue samples, sample analysis by spectral acquisition was carried out as it would be 
in the clinic. i.e all and any normal tissue was analysed, and no particular area was targeted 
(eg white/grey matter). Similarly, for tumoral sections, all cancerous areas were analysed 
irrespective of the origin of the structure, again mimicking clinical practice. 
 
Data pre-processing 
 
Pre-processing was carried out on the raw data using LabSpec 6 spectroscopy 
software suite (HORIBA Scientific, Japan) and MATLAB version 7.11.0 (R2010b) (The 
MathWorks, Inc., USA) using in-house written software. Pre-processing methods were kept 
to a minimum to enable better reproducibility; background subtracted was performed through 
the application of a fifth order polynomial and smoothed using 7 point smoothing (Labspec 6) 
and vector normalised (Matlab) using in-house written code.  
 
Atomic force microscope (AFM) 
 The atomic force microscope (AFM) model that was used to image the samples for 
surface morphology for this study is the MFP-3D-BIO (Asylum Research, USA), with 
Olympus silicon AC160 cantilevers. The tips were 160 nm long with resonant frequencies 
typical of 320 kHz. A/C mode was employed for operation to reduce tip/sample. 
 
Results and Discussion 
 
Dewaxing efficiency of spectroscopic substrates     
 
Raman spectra of the three substrates: low-E, Spectrosil and CaF2, were acquired 
under identical conditions to generate spectral ‘fingerprints’ of the substrates, shown in 
Figure 2, and thus ascertain the impact of their contribution to the spectral background.  
 
It can be observed that low-E has the highest intensity baseline and CaF2 has the 
lowest intensity baseline of the three substrates; indicating that spectra taken from samples on 
CaF2 are less affected by substrate background than either low-E or Spectrosil and should 
display background peaks of lower intensities. 
 
The spectra of dewaxed tissue samples on the three different substrates were 
compared to further investigate the level of influence substrate type has on the outcome of 
spectra. Figure 3 displays average spectra of dewaxed tissue on the three substrates and a 
paraffin spectrum for comparison 
 
A paraffin spectrum displays significant peaks at 888 cm
-1
, 1061 cm
-1
, 1131 cm
-1
, 
1171 cm
-1
, 1294 cm
-1
, 1417 cm
-1
, 1440 cm
-1
, 1462 cm
-1
 (Figure 3), which can be assigned to 
C-C stretching and CH2 and CH3 deformations within the molecule 
25
. It can be seen from 
Figure 3 that the spectra from the dewaxed tissue samples on Spectrosil and CaF2 exhibit 
residual paraffin peaks. However, dewaxed tissue spectra on low-E do not display visible 
paraffin peaks.  
 
In order to further investigate any substrate effect on the dewaxing process, paraffin 
wax was analysed on the substrates without the presence of tissue specimens. Paraffin wax 
was cut at 10 µm sections and mounted onto the three different substrates. The substrates 
were then dewaxed by the same method as the FFPP tissue samples and analysed; Figure 4 
displays the resulting spectra. Residual wax, still present on both the Spectrosil and CaF2 
substrate, could be seen visually both macroscopically and microscopically, shown in Figure 
5, and its presence was confirmed by paraffin peak contributions in their spectra. The low-E 
substrate did not retain any visual paraffin wax and no paraffin peaks were present in the 10 
spectra taken from the substrate. This shows, for the first time, a substrate effect that occurs 
during the dewaxing process inferring that as a result of surface chemistry or morphology, 
low-E slides facilitate the removal of wax more readily than CaF2 and Spectrosil. From 
Raman analysis and visual inspection, it is clear that, using the same dewaxing protocol, the 
low-E substrate is fully dewaxed, yet the CaF2 and Spectrosil substrates retain paraffin wax.  
 
Atomic force microscopy (AFM) was utilised to assess the three substrates’ surface 
roughness. The AFM images of the three substrates are displayed in Figure 6, showing the 
surface morphology at a nanoscopic level. The low-E substrate was observed to have a far 
smoother surface than either CaF2 or Spectrosil with an average surface roughness of 1.10 nm 
compared to 4.76 nm and 3.88 nm respectively. Low-E slides are coated with metal oxide36; 
this could explain why their surface is far smoother than the other substrates which are only 
polished.    
 
The clinical application of spectral histopathology is the ultimate aim of this field. As 
such, the adherence to current clinical process will be advantageous. The use of Low-E slides 
holds a number of advantages for this, such as low cost, their microscope slide size and 
robustness when compared to other substrates. Although substrate spectral background is 
higher, all tissue spectral peaks that are detected when using other substrates are present in 
the spectrum. 
 
Spectral Histopathology: Dewaxing Efficiency by Tissue Types 
Although low-E substrates clearly perform better in terms of wax removal from the 
tissue sections using routine clinical protocols, CaF2 is commonly used in Raman 
spectroscopic studies due to its low contribution to the spectral background (Figure 2). It is of 
interest to investigate whether the tissue type mounted on these substrates also contributes to 
the residual signals. The vector normalised mean Raman spectra of dewaxed sections of 
normal (157 spectra from 7 patients), metastatic (668 spectra from 29 patients) and GBM 
(127 spectra from 5 patients) brain tissue on CaF2 substrates are displayed in Figure 7. It can 
be observed from the averaged spectrum of normal tissue that the paraffin peaks (asterisked 
peaks) are not fully removed by the dewaxing process, but notably the characteristic features 
are of a much lower intensity than those in the spectra of metastatic and GBM tissue Figure 8 
shows the average intensity and standard deviation of the intense paraffin peaks at 1061, 
1131 and 1294 cm
-1
. As can be seen, there is a trend to greater paraffin retention in normal to 
the cancerous states, metastatic tissue retaining the most paraffin, after the same processing 
procedures. Further imaging studies are planned to examine the impact of the substrate upon 
paraffin retention, as there seems to be an interplay of tissue dependence and substrate 
dependence where the paraffin clumps upon the substrate surface, as can be seen in Figure 5. 
 
Abnormal tissue can be of very different morphology than normal tissue. A difference 
in tissue density could provide an explanation for the inconsistency of the dewaxing 
efficiency, and thus the variation of paraffin peak intensity between the normal brain and 
cancerous brain tissue spectra. For breast cancer Li et al. state that the amount of fibro-
glandular and adipose tissue is strongly related to the risk of developing cancer. They explain 
that, although no direct evidence has been found to link dense mammographic tissue with the 
increased chance of developing breast cancer, the correlations observed have encouraged the 
use of tissue density for breast cancer monitoring. They go on to support the observations of 
this correlation through their findings that the mammograms of cancerous breast tissue are far 
denser than those of normal breast tissue 
37
. Berrtholdo  et al. correlate increased choline 
signals from Magnetic Resonance Spectroscopy as a  measure of malignancy in brain 
tumours  due to increased glial cell density as choline is a marker of cellular membrane 
turnover reflecting cellular proliferation
38
. Indeed, it should be noted that, whereas in this 
study complete removal of wax was observed for tissue samples on low-E slides, O’ Faoláin 
et al. 
39
  reported incomplete was removal from normal parenchymal tissue from the placenta, 
dewaxed using a xylene based protocol also measured in low-E slides. 
 
The results indicate that tissue processing still remains an issue for Spectropathology, 
particularly using Raman spectroscopy. For clinical relevancy, however, and indeed 
acceptance of the techniques by the clinical community, it is important that the sample 
preparation and measurement protocols for Raman spectroscopic analyses are consistent with 
current clinical practice. Choice of substrate for routine clinical analyses may be dominated 
by economic considerations, thus favouring low E slides. Paraffin embedding facilitates 
tissue cutting, but also is commonly employed, worldwide, for archiving tissue samples. The 
availability of a wide range of pathologically characterized samples for study potentially 
enables extensive retrospective studies using spectroscopic and other techniques. The 
embedding process and wax itself can, however, contribute significantly to the spectroscopic 
signature of the tissue 
40
. An alternate method of “digital dewaxing” biological specimens to 
remove paraffin contributions of the spectrum has been proposed by Gobinet et al., 
recognising that chemical dewaxing methods are known to be inefficient for the complete 
removal of wax in tissue and can cause alterations to the samples. Their method of dewaxing 
consists of an estimation of the paraffin sources in the spectrum using Independent 
Component Analysis (ICA), followed by a Non-negatively Constrained Least Squares 
(NCLS) method to subtract the contributions. This enables removal of the paraffin signals to 
allow analysis of the underlying tissue spectrum 
33
. However, although “digital dewaxing” 
has been demonstrated
41
, it is also often important to compare spectroscopic profiling with 
parallel histological analyses, requiring chemical dewaxing of sections, a process which adds 
to the sample variability. The observation of variable dewaxing efficiencies depending on 
tissue pathology ads complexity to the challenge, perhaps requiring a combination of 
established clinical dewaxing protocols with computational procedures. 
 
Conclusion 
This study shows the influence that Raman substrates have on resulting spectra from 
Raman analysis. Spectral backgrounds of the substrates show that the baseline of low-E is the 
highest and CaF2 the lowest of the three substrates. It has been established through 
observation and investigation that CaF2 and Spectrosil substrates retain paraffin wax after the 
dewaxing procedure is carried out whereas low-E does not. This is attributed to the difference 
in surface roughness and chemistry between substrates. AFM demonstrated that low-E 
substrates are far smoother than either CaF2 or Spectrosil substrates with average roughness 
of 1.10 nm compared to 4.76 nm and 3.88 nm respectively. 
 This study has also observed the difference between the dewaxing efficiency between 
normal brain and cancerous brain tissue. This has been attributed to a change in density 
between normal and cancerous, which causes the denser cancerous tissue to retain wax better 
than the, less dense, normal tissue. It is important to note therefore that tissue processing 
procedures for spectral histopathology of normal tissue may not be optimised for abnormal 
regions. 
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List of Tables and Figures 
Table 1 Patient details with histological subtype and metastatic origin.    
Figure 1 Microscopic images of H&E stained tissue samples of normal brain, metastatic (from oesophagus and 
stomach, breast, colon/rectum, lung and melanoma as labelled above) and GBM brain WHO grade IV (x 100). 
Scale bar represents 50 microns. 
Figure 3 Averaged spectra of 458 CaF2 acquisitions, 210 low-E acquisitions and 465 Spectrosil acquisitions 
from all tissue specimens and a background-subtracted spectrum of paraffin wax. The tissue spectra have been 
vector normalised and offset for visual clarity. The asterisks above the peaks correspond to the paraffin 
contributions.    
Figure 4 Vector normalised, background corrected spectra of substrates after dewaxing from: 1 CaF2 
acquisition, 1 Spectrosil acquisition and 10 averaged low-E acquisitions. The spectrum of paraffin wax is 
included as a reference. The spectra have been appropriately scaled and offset for visual clarity.  
 Figure 5 Microscopic Raman images at x 10 of the substrate surfaces after dewaxing. Wax residuals can be 
observed on the CaF2 and Spectrosil substrates. Scale bars represent 0.5 mm. 
Figure 6 AFM images of Spectrosil, CaF2 and Low-E substrates. 
 
Figure 7 Averaged immersion spectra of 127 GBM acquisitions, 668 metastatic acquisitions and 157 normal 
brain acquisitions. Normal tissue spectrum is shown with its standard deviation in red (top), GBM tissue 
spectrum is shown with its standard deviation in green (middle), and metastatic tissue spectrum is shown with 
its standard deviation in blue (bottom). Spectra have been vector normalised, the backgrounds have been 
corrected using a 5th order polynomial fit and subtraction and 7 points of smoothing. The asterisks correspond 
to paraffin peaks from residual wax in the tissue. 
Figure 8  The average intensity and standard deviation of three intense paraffin peaks at 1061, 1131 
and 1294 cm-1 for the three tissue types; Normal tissue (blue), Glioblastoma multiforme (red) and 
Metastatic brain cancer (green) 
 
 
